Objective: To explore changes in eating behaviours, inherent weight gain and the metabolic consequences in severely mentally ill patients treated with antipsychotic medications. Method: We conducted a comprehensive review of studies that investigated eating behaviours in mentally ill patients taking antipsychotic treatments. We included records that considered weight change and/or varying degrees of adverse metabolic effects and related metabolic disturbances, such as obesity, dyslipidaemia, type 2 diabetes mellitus, hypertension, metabolic syndrome and cardiovascular diseases. We adopted a systematic approache (PRISMA) and considered 4 electronic databases: PubMed, Medline, Embase, and Psychinfo. Moreover, we conducted a manual synthesis o...
ABSTRACT: BACKGROUND: Patients with antipsychotic-induced weight gain (WG) regularly report on unsuc...
BACKGROUND: Weight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a major hea...
Purpose: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of ...
Disturbed eating behaviours have been widely reported in psychotic disorders since the early 19th ce...
The prevalence of overweight and obesity is higher in people with mental illness than in the general...
PURPOSE: To describe the weight gain-related side-effects of psychotropic drugs and their consequenc...
Introduction: Patients living with schizophrenia have a marked risk of clinically significant weight...
Background: Antipsychotic-induced weight gain (AIWG) and other adverse metabolic effects represent s...
Objectives: To review current evidence for the hypothesis that treatment with antipsychotic medicati...
Although clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyrami...
Background and Aims: Overweight, obesity and binge eating disorder are commonly reported in persons ...
Overweight and obesity are common concerns in individuals with severe mental disorders. In particula...
Background. Second generation antipsychotics (SGAs) are used widely for the treatment of schizophren...
Many aspects of the motivation to eat are involved in the impairment of adequate food intake and bod...
Antipsychotic medications are a necessary treatment forindividuals with psychoses. To be maximally b...
ABSTRACT: BACKGROUND: Patients with antipsychotic-induced weight gain (WG) regularly report on unsuc...
BACKGROUND: Weight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a major hea...
Purpose: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of ...
Disturbed eating behaviours have been widely reported in psychotic disorders since the early 19th ce...
The prevalence of overweight and obesity is higher in people with mental illness than in the general...
PURPOSE: To describe the weight gain-related side-effects of psychotropic drugs and their consequenc...
Introduction: Patients living with schizophrenia have a marked risk of clinically significant weight...
Background: Antipsychotic-induced weight gain (AIWG) and other adverse metabolic effects represent s...
Objectives: To review current evidence for the hypothesis that treatment with antipsychotic medicati...
Although clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyrami...
Background and Aims: Overweight, obesity and binge eating disorder are commonly reported in persons ...
Overweight and obesity are common concerns in individuals with severe mental disorders. In particula...
Background. Second generation antipsychotics (SGAs) are used widely for the treatment of schizophren...
Many aspects of the motivation to eat are involved in the impairment of adequate food intake and bod...
Antipsychotic medications are a necessary treatment forindividuals with psychoses. To be maximally b...
ABSTRACT: BACKGROUND: Patients with antipsychotic-induced weight gain (WG) regularly report on unsuc...
BACKGROUND: Weight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a major hea...
Purpose: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of ...